BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ)

$2.84 0.02 (0.7092%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 73

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ) News Sources

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

28-04-2026

yahoo.com

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts

19-05-2026

yahoo.com

BioLineRx to Report First Quarter 2026 Results on May 27, 2026

20-05-2026

yahoo.com

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

22-05-2026

yahoo.com

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

27-05-2026

yahoo.com

BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX)

27-05-2026

advfn.com

BLRX: First Quarter 2026 Results

28-05-2026

yahoo.com

BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

03-06-2026

yahoo.com

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

08-07-2026

yahoo.com

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

20-07-2026

yahoo.com

BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ) Sentiment Trend

0 25 50 75 100 73 84 83 78 74 80 85 8 82 82 28-04-2026 19-05-2026 20-05-2026 22-05-2026 27-05-2026 28-05-2026 03-06-2026 08-07-2026 20-07-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ) FAQs

toggle

What is the current price of BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ)?

The current price of BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ) is $2.84.


toggle

BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ) absolute price change since previous trading day?

The absolute price change of BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ) since the previous trading day is $0.02.


toggle

BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ) percentage price change since previous trading day?

The percentage price change of BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ) since the previous trading day is 0.7092%.


toggle

What is the most recent average sentiment score for BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ)?

The most recent average sentiment score for BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ) is 73 out of 100.


toggle

What is the most recent average sentiment for BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ)?

The most recent sentiment for BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ) is .


SEC-8K** Filing Available For BIOLINERX LTD-SPONS ADR (BLRX:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.